Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › IL-6 inhibitors

IL-6 inhibitors

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis
Rheumatology Sys. Review
JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis Specific Biologic Drugs Show Better Results for Rheumatoid Arthritis
This meta-analysis of 99 studies evaluated patient-reported outcomes (PROs) in patients with rheumatoid arthritis treated with b/tsDMARDs. T…
New analysis shows that certain types of biologic drugs may better reduce activity limits and improve mental health for people with rheumato…
Jun 25, 2026
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Allergy & Immunology Sys. Review
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Frontiers Jun 4, 2026